Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.

JAMA oncology - 1 Apr 2018

Hearn Jason W D, Xie Wanling, Nakabayashi Mari, Almassi Nima, Reichard Chad A, Pomerantz Mark, Kantoff Philip W, Sharifi Nima

Abstract excerpt

IMPORTANCE: The variant HSD3B1 (1245C) allele enhances dihydrotestosterone synthesis and predicts resistance to androgen-deprivation therapy (ADT) for biochemically recurrent prostate cancer after prostatectomy and for metastatic disease. Whether this is true after radiotherapy is unknown. OBJECTIVE: To determine whether the HSD3B1 (1245C) allele predicts worse clinical outcomes from ADT for biochemical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Chemotherapy, Adjuvant

Share to Combined Modality Therapy

Share to Multienzyme Complexes

Share to Neoplasm Recurrence, Local

Share to Steroid Isomerases

Source

Open in PubMed Open full text

Identifiers

PMID: 29049492
DOI: 10.1001/jamaoncol.2017.3164
PMCID: PMC5933377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.PMID 29049492Read ↗

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Semantic proximity Read ↗

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.Semantic proximity Read ↗

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity Read ↗

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.